Business Wire

RIGHTWARE

Share
Rightware Releases Kanzi One, the First All-in-One Automotive HMI Tool for the Advanced Intelligent Cockpit

Rightware today released Kanzi One, concluding a highly successful and oversubscribed beta program announced in September. The first automotive HMI toolchain to be fully compatible with Android™, Kanzi One delivers industry-leading 3D graphics and a new UI workflow, empowering automakers to create compelling new user experiences with visual excellence and maximum productivity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220103005425/en/

“As announced at IAA in Munich, Kanzi One is a game-changer for creativity and productivity by automakers,” said Rightware CEO Freddie Geier. “We are grateful for the positive feedback from customers and partners since our product launch, and we eagerly await the new Signature UIs they create with Kanzi One.”

Rightware’s goal with Kanzi One is to inspire OEMs and Tier 1 suppliers with impressive rendering capabilities and a powerful 3D graphics engine, the deepest Android integration for next generation infotainment systems, and a straightforward workflow that unleashes HMI possibilities.

Kanzi One lets manufacturers deliver future-looking user experiences for advanced HMIs in less than half the time with teams half the size and with significantly less coding compared with traditional methods.

All-in-One Solution

In addition to the core Kanzi framework consisting of Kanzi Studio and Kanzi Engine, Kanzi One delivers further value to automakers by including a growing list of feature packs.

Initially, five feature packs are included: Kanzi Connect makes it easy to share data, content, and services across screens and devices; Kanzi Maps enhances navigation with creative visualization; Kanzi Particles enables astounding visual effects and animations; Kanzi Autostereoscopy enables realistic depth effects; and the new Kanzi VR makes it easy to validate designs in an early phase by placing live UIs inside a virtual car interior and interacting with the screens with or without a virtual reality headset.

“We are certain that Kanzi One will transform the in-car user interfaces of today into tomorrow’s Signature UIs—highly appealing, easy-to-use, and true to their brand,” said Geier. “We invite all friends and observers of innovation in the automotive industry to explore the possibilities of Kanzi One, and count on us to drive HMI development to the next level.”

Due to the rapidly rising health risks associated with covid, Rightware made the decision not to attend CES 2022. Instead, the company will kick off a customer road show to present Kanzi One as conditions permit. To request a virtual or in-person meeting and to read descriptions of the latest Kanzi One demonstrations, please visit www.rightware.com/kanzi-one-at-ces-2022 or contact sales@rightware.com .

About Rightware
Rightware is the company behind the Kanzi family of tools and services for design and development of advanced digital user interfaces. Our mission is to help automakers increase brand value with highly customized signature user interfaces. As a ThunderSoft company, our combined skills and assets allow us to deliver fully integrated HMI solutions, engineering support, and design services. Rightware is headquartered in Finland and has a presence in China, Germany, Italy, Japan, South Korea, UK, and USA. Kanzi is the market-leading automotive UI tool trusted by over 50 automotive brands across the globe. www.rightware.com

Android is a trademark of Google LLC.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alta Semper Signs Definitive Agreements to Acquire a Majority Stake in Nature’s Rule, a MENA-Focused Leader in Dietary Supplements and Sports Nutrition19.1.2026 09:13:00 CET | Press release

Alta Semper, a London-based private equity firm focused on healthcare and consumer investments across growth markets, today announced that it has signed definitive agreements to acquire a majority stake in Nature’s Rule, a leading sports nutrition and dietary supplements company headquartered in the UAE, with an established manufacturing presence in Egypt. The acquisition is a majority investment in Prowell Holding, the parent company of Nature’s Rule, the operator of the largest fully dedicated sports nutrition and dietary supplements manufacturing facility in MENA. The company’s infrastructure and in-house R&D capabilities support a portfolio of private-label clients and proprietary brands, including Redrex, its flagship, market-leading sports nutrition brand developed in collaboration with global bodybuilding icon Mamdouh Elssbiay (“Big Ramy”). The founders will retain a significant stake and continue to lead the business. The partnership will execute a focused value-creation plan t

The UK Chooses Bridge Over Troubled Water as the Nation’s Favourite Song of Hope in Solidarity With Refugees19.1.2026 09:00:00 CET | Press release

Simon and Garfunkel classic named the UK’s top #HopeHitOver 1000 people from across the country nominated songs to show their solidarity with refugees around the world this winterThe most popular Hope Hits available on the Hope On Repeat playlist to get you through Blue Monday Simon and Garfunkel’s Bridge Over Troubled Water has been votedas the UK’s number one #HopeHit ― as part of UK for UNHCR’s ‘Hope on Repeat’ campaign, raising awareness of the hardships facing refugees across the globe this winter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119165712/en/ Simon & Garfunkel's Bridge Over Troubled Water voted the UK's number one #HopeHit With 10% of the public vote, Bridge Over Troubled Water emerged as the UK’s most popular #HopeHit. Since November, the UN Refugee Agency’s national charity partner has invited people to nominate their #HopeHits - the tunes that connect us and warm our hearts as the weather gets cold

Prodalim Expands SOLOS Capabilities with New Dealcoholization Site in Spain19.1.2026 08:33:00 CET | Press release

Prodalim, a global leader in juice and specialty ingredients solutions, announced today the expansion of its SOLOS division with the opening of a dedicated dealcoholization and aroma recovery site in Valencia, Spain. The new facility is fully operational and strengthens Prodalim’s ability to support the rapidly growing no- and low-alcohol (NoLo) beverage market across Europe. During the coming months, an additional SOLOS site in California is planned to be inaugurated, further expanding overall capacity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260118626123/en/ Inauguration of the SOLOS Valencia Site for Advanced NoLo Solutions The global NoLo category continues to expand, driven by consumer demand for mindful drinking and healthier lifestyle choices. Industry forecasts estimate the NoLo global market at approximately USD 25 billion in 2025, with expected annual growth of 8–10% as the category expands across beers, win

ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer19.1.2026 08:30:00 CET | Press release

Based on DESTINY-Breast09 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s ENHERTU in combination with pertuzumab significantly improved progression-free survival versus current first-line standard of care in HER2 positive metastatic breast cancer The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) in combination with pertuzumab for the first-line treatment of adult patients with unresectable or metastatic HER2 positive breast cancer. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The application is based on data from the DESTINY

Syngenta to Address Global Agricultural Challenges at WEF, Championing AI to Empower Farmers and Create Open Technology Access19.1.2026 08:00:00 CET | Press release

AI and digital tools are unlocking unprecedented opportunities to strengthen farms and secure food security. New IPSOS study reveals technology adoption gap, underscoring urgent need for equitable technology access. Syngenta champions "Agricultural Intelligence" at World Economic Forum, showcasing Cropwise AI solutions that put cutting-edge tools in the hands of all farmers, especially smallholders. As farmers globally grapple with unprecedented economic, geopolitical, and environmental pressures; the agricultural sector faces a continued contraction. An alarming decrease in active farms worldwide and rising financial distress underscore the urgent need for innovation and technology to ensure a resilient food system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260118646017/en/ Jeff Rowe, Syngenta Group CEO "Farmers today are navigating one of the most complex periods in modern agriculture, facing pressures that demand urg

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye